Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of NAD+ and Selank — mechanism, dosing, side effects, legal status, and pricing.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells, not a peptide. It is classified here alongside peptides for user convenience in the anti-aging / metabolic category. NAD+ plays a central role in cellular energy metabolism and redox reactions and is studied for its involvement in mitochondrial function, DNA-damage signaling via sirtuins and PARPs, and age-associated metabolic decline. IV NAD+ is not FDA-approved for any clinical indication; it is administered off-label through compounding pharmacies and functional-medicine clinics with limited rigorous outcome data.
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro C-terminus for metabolic stability. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it is registered as an anxiolytic drug in Russia but is not approved by the FDA or EMA.
NAD+
Selank
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
NAD+
Selank
COA corpus from Disclosed Labs — independently tested batches only.
NAD+
146
COAs
99.4%
Avg purity
15
Labs
Selank
81
COAs
99.6%
Avg purity
18
Labs
Selank is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. NAD+ remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
The strongest human evidence for raising circulating NAD+ comes from oral-precursor trials. A randomized, double-blind, placebo-controlled study of nicotinamide riboside combined with pterostilbene (NRPT) showed sustained dose-dependent increases in whole-blood NAD+ over 8 weeks in healthy adults (Dellinger et al., npj Aging and Mechanisms of Disease, 2017). A Yoshino/Baur/Imai review summarizes the biology and emerging therapeutic potential of NR and NMN, including preclinical healthspan data in aged mice (Cell Metabolism, 2018). Direct IV NAD+ has only small pilot pharmacokinetic data: Grant et al. infused 750 mg over 6 hours in 8 healthy men and documented altered plasma and urine NAD+ metabolome without clinical-outcome endpoints (Frontiers in Aging Neuroscience, 2019). No adequately powered RCTs support IV or SubQ NAD+ for anti-aging, cognition, addiction, or Parkinson's disease; clinic marketing claims outrun the published outcome evidence.
Key references
Selank's clinical evidence base is almost entirely Russian. Zozulia et al. (2008, Zh Nevrol Psikhiatr Im S S Korsakova; PMID 18454096) compared selank to medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting comparable anxiolytic efficacy plus antiasthenic/psychostimulant effects, together with changes in serum enkephalin-degrading enzyme activity. Mechanistic work includes Inozemtseva et al. (2008, Dokl Biol Sci; PMID 18841804) showing intranasal Selank increases hippocampal BDNF mRNA and protein in rats, Volkova et al. (2016, Front Pharmacol; PMID 26924987) demonstrating modulation of GABAergic gene expression, and Vyunova et al. (2018, Protein Pept Lett; PMID 30255741) proposing a positive allosteric GABA-A mechanism. No US or EU regulatory clinical trials have been conducted; safety data outside Russia is limited.
NAD+ (Metabolic) and Selank (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs